Induction of the Hif regulated genes, as a consequence of the microenvironment or genetic changes, is known to have an important role in the growth of experimental tumours. HIF2A is predominantly expressed in highly vascularized tissues of adult humans and endothelial cells of the embryonic and adult mouse, whereas HIF1A has been observed in varying subsets of tumour cells from various solid tumours. HIF2A is also a potent activator of the tie2 gene, which is known to be selectively expressed in endothelial cells.
| Inventor | Institute |
|---|---|
| Helen Turley | University of Oxford |
| SKU: | 151263 |
|---|---|
| Product description: | Induction of the Hif regulated genes, as a consequence of the microenvironment or genetic changes, is known to have an important role in the growth of experimental tumours. HIF2A is predominantly expressed in highly vascularized tissues of adult humans and endothelial cells of the embryonic and adult mouse, whereas HIF1A has been observed in varying subsets of tumour cells from various solid tumours. HIF2A is also a potent activator of the tie2 gene, which is known to be selectively expressed in endothelial cells. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | GST-human EPAS-1 (HIF2A) amino acids 535-631 fusion protein |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Cat. #: | 151263 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Genetics;Metabolism;Tissue-specific biology |
| Application: | ELISA ; IHC ; WB |
| Target: | Hypoxia-inducible factor 2, alpha subunit (HIF2A) |
| Reactivity: | Human |
| Clone: | EP190b |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Induction of the Hif regulated genes, as a consequence of the microenvironment or genetic changes, is known to have an important role in the growth of experimental tumours. HIF2A is predominantly expressed in highly vascularized tissues of adult humans and endothelial cells of the embryonic and adult mouse, whereas HIF1A has been observed in varying subsets of tumour cells from various solid tumours. HIF2A is also a potent activator of the tie2 gene, which is known to be selectively expressed in endothelial cells. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Pacak et al. 2013. J Clin Oncol. 31(13):1690-8. PMID: 23509317. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. Neumeister et al. 2012. J Natl Cancer Inst. 104(23):1815-24. PMID: 23090068. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. Giatromanolaki et al. 2003. J Pathol. 200(2):222-8. PMID: 12754744. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. Hui et al. 2002. Clin Cancer Res. 8(8):2595-604. PMID: 12171890. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Beasley et al. 2002. Cancer Res. 62(9):2493-7. PMID: 11980639. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Talks et al. 2000. Am J Pathol. 157(2):411-21. PMID: 10934146. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Wiesener et al. 1998. Blood. 92(7):2260-8. PMID: 9746763. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.